Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 2, MULTICENTER, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CB 03 01 (CORTEXOLONE 17α-PROPIONATE) SOLUTION FOR THE TREATMENT OF ANDROGENETIC ALOPECIA IN MALES

Trial Profile

A PHASE 2, MULTICENTER, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CB 03 01 (CORTEXOLONE 17α-PROPIONATE) SOLUTION FOR THE TREATMENT OF ANDROGENETIC ALOPECIA IN MALES

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2018

At a glance

  • Drugs Clascoterone (Primary) ; Clascoterone (Primary)
  • Indications Alopecia
  • Focus Therapeutic Use
  • Sponsors Cassiopea
  • Most Recent Events

    • 16 Jul 2018 Results of planned six-month interim analysis presented in the Cassiopea media release.
    • 16 Jul 2018 According to a Cassiopea media release, the company plans to present planned six-month interim analysis data at a future medical meeting and also for consideration for publication in a peer-reviewed journal.
    • 28 Feb 2018 According to a Cassiopea media release, an interim analysis will be made after 6 months to make an assessment of the best dosing regimen and top-line results are expected in late H1 2018/early 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top